4.1 Article

Screening for hypophosphatasia: does biochemistry lead the way?

Journal

JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM
Volume 35, Issue 2, Pages 169-178

Publisher

WALTER DE GRUYTER GMBH
DOI: 10.1515/jpem-2021-0104

Keywords

alkaline phosphatase; heterozygous ALPL mutation; hypophosphatasia; inorganic pyrophosphate; phosphoethanolamine; pyridoxal phosphate; screening

Funding

  1. INTERREG V programme RARENET
  2. FH Zeit fur Forschung ('KETOplus') of the Ministry of Culture and Science of the German State of North Rhine-Westphalia [005-1703-0016]

Ask authors/readers for more resources

A diagnostic algorithm based on decreased AP activity effectively identified patients with ALPL gene mutations, particularly in cases where other underlying diseases were excluded. Three patients with decreased AP activity, elevated PLP and PEA levels were diagnosed with childhood HPP, with one starting enzyme replacement therapy.
Objectives Patients with childhood hypophosphatasia (HPP) often have unspecific symptoms. It was our aim to identify patients with mild forms of HPP by laboratory data screening for decreased alkaline phosphatase (AP) within a pediatric population. Methods We conducted a retrospective hospital-based data screening for AP activity below the following limits: Girls: <= 12 years: 12 years: 14 years: <70 U/L. Screening positive patients with otherwise unexplained hypophosphatasemia were invited for further diagnostics: Re-test of AP activity, pyridoxal 5 '-phosphate (PLP) in hemolyzed whole blood, phosphoethanolamine (PEA) in serum and urine, and inorganic pyrophosphate in urine. Sequencing of the ALPL gene was performed in patients with clinical and/or laboratory abnormalities suspicious for HPP. Results We assessed a total of 14,913 samples of 6,731 patients and identified 393 screening-positive patients. The majority of patients were excluded due to known underlying diseases causing AP depression. Of the 30 patients who participated in the study, three had a decrease in AP activity in combination with an increase in PLP and PEA. A heterozygous ALPL mutation was detected in each of them: One patient with a short stature was diagnosed with childhood-HPP and started with enzyme replacement therapy. The remaining two are considered as mutation carriers without osseous manifestation of the disease. Conclusions A diagnostic algorithm based on decreased AP is able to identify patients with ALPL mutation after exclusion of the differential diagnoses of hypophosphatasemia and with additional evidence of increased AP substrates.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available